Omission of 5-Fluorouracil Bolus From Multidrug Regimens for Advanced Gastrointestinal Cancers: A Multicenter Cohort Study
Journal of the National Comprehensive Cancer Network · 2024-10 · 22 (8) · 521-527
DOI: 10.6004/jnccn.2024.7029 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2024-10. Verfasst von Chengwei Peng und 10 weiteren Autor:innen. Beteiligte Einrichtung: New York University, New York, NY. Hauptthemen laut MEDLINE: Fluorouracil, Antineoplastic Combined Chemotherapy Protocols, Gastrointestinal Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 42 Literaturangaben.
Abstract (Originalsprache)
Background
5-Fluorouracil (5-FU) is a major component of gastrointestinal cancer treatments. In multidrug regimens such as FOLFOX, FOLFIRI, and FOLFIRINOX, 5-FU is commonly administered as a bolus followed by an infusion. However, the pharmacologic rationale for incorporating the 5-FU bolus in these regimens is unclear, and there are other effective regimens for gastrointestinal cancers that do not include the bolus. The purpose of this study was to determine whether omission of the 5-FU bolus was associated with a difference in survival and toxicity.
Methods
A real-world database from Flatiron Health was queried for patients with advanced colorectal, gastroesophageal, and pancreatic cancers who received first-line FOLFOX, FOLFIRI, and FOLFIRINOX regimens. Cox proportional hazards and Kaplan-Meier analyses were performed to compare survival outcomes between patients who received the 5-FU bolus and those who did not. Inverse probability of treatment weighted (IPTW) analysis was performed to adjust for treatment selection bias.
Results
This study included 11,765 patients with advanced colorectal (n=8,670), gastroesophageal (n=1,481), and pancreatic (n=1,614) cancers. Among all first-line 5-FU multidrug regimens, 10,148 (86.3%) patients received a 5-FU bolus and 1,617 (13.7%) did not. After IPTW analysis, we found that omitting the bolus was not associated with a decrease in overall survival (hazard ratio, 0.99; 95% CI, 0.91–1.07; P =.74). However, omitting the bolus was associated with reductions in neutropenia (10.7% vs 22.7%; P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- New York University, New York, NY.
- Northwestern University, Chicago, IL.
- Yale School of Medicine, New Haven, CT.
- Weill Cornell Medicine, New York, NY.
- Vanderbilt-Ingram Cancer Center, Nashville, TN.
- Sheba Medical Center, Ramat Gan, Israel.
Zitieren
APA
Peng, C., Saffo, S., Oberstein, P. E., Shusterman, M., Thomas, C., Becker, D. J., Berlin, J. D., Leichman, L. P., Boursi, B., Nagar, A. B., & Yu, S. (2024). Omission of 5-Fluorouracil Bolus From Multidrug Regimens for Advanced Gastrointestinal Cancers: A Multicenter Cohort Study. Journal of the National Comprehensive Cancer Network, 22(8), 521-527. https://doi.org/10.6004/jnccn.2024.7029
Vancouver
Peng C, Saffo S, Oberstein PE, Shusterman M, Thomas C, Becker DJ, et al. Omission of 5-Fluorouracil Bolus From Multidrug Regimens for Advanced Gastrointestinal Cancers: A Multicenter Cohort Study. Journal of the National Comprehensive Cancer Network. 2024;22(8):521-527. doi:10.6004/jnccn.2024.7029
BibTeX
@article{Peng2024,
author = {Peng, Chengwei and Saffo, Saad and Oberstein, Paul E and Shusterman, Michael and Thomas, Charlene and Becker, Daniel J and Berlin, Jordan D and Leichman, Lawrence P and Boursi, Ben and Nagar, Anil B and Yu, Shun},
title = {Omission of 5-Fluorouracil Bolus From Multidrug Regimens for Advanced Gastrointestinal Cancers: A Multicenter Cohort Study},
journal = {Journal of the National Comprehensive Cancer Network},
year = {2024},
volume = {22},
number = {8},
pages = {521--527},
doi = {10.6004/jnccn.2024.7029}
}
EUVIMED